AZ bags key lung cancer approval for Imfinzi

Becomes the first PD-1/PD-L1 inhibitor approved to treat inoperable stage III NSCLC patients

Original Article: AZ bags key lung cancer approval for Imfinzi

More From BioPortfolio on "AZ bags key lung cancer approval for Imfinzi"

• Related Companies
• Related Events
• Related Clinical Trials
• Related PubMed Entries
• Related Medications